January 24, 2019 | North Carolina, US
Trilogy hosted a discussion on the implications that the disclosure and transparency regulations will have on producing clinical regulatory documentation and provided insight from an actual anonymization procedure, together with our speakers:
- Jo Anne-Marie Blyskal (Head of Global Regulatory Medical Writing and Data Disclosure, Teva)
- Dr. Julia Forjanic Klapproth (Senior Partner, President at Trilogy Writing & Consulting)